Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2.
about
T cell-specific siRNA delivery suppresses HIV-1 infection in humanized miceEpigenetic deregulation of microRNAs in rhabdomyosarcoma and neuroblastoma and translational perspectivesPreclinical and clinical development of siRNA-based therapeuticsProgress toward in vivo use of siRNAs-IIWavelength-Selective Light-Induced Release from Plasmon Resonant Liposomes.Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA.Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering.Sendai F/HN viroplexes for efficient transfection of leukemic T cells.MicroRNAs as novel regulators of angiogenesis.MicroRNA regulation of cancer stem cells and therapeutic implications.Strategies for targeted nonviral delivery of siRNAs in vivo.RNA interference in the clinic: challenges and future directions.Strategies for tumor-directed delivery of siRNA.MicroRNAs in rhabdomyosarcoma: pathogenetic implications and translational potentiality.Delivery of RNAi therapeutics: work in progress.Therapeutic Potentials of Noncoding RNAs: Targeted Delivery of ncRNAs in Cancer Cells.Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles.Molecular Mechanisms and Biological Functions of siRNA.Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer.Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer.In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments
P2860
Q24603574-45200B05-B0E2-49F5-ABB2-883E198A69A0Q26999187-A9ED9780-0F7E-4586-8205-E68DAC832BD6Q28085290-09D59775-C5AE-4721-97F0-E06D8895BD1EQ28255877-5C48C98E-4BFC-4890-8536-996BFB1D7440Q33973597-1466E236-A955-4786-A5AD-4DFAE6206916Q34640040-4A10A648-2C2C-4273-A60E-73DFFF83AC99Q36174842-79E956EC-21BF-4473-93CB-CF24E9909B6BQ37094610-3AD59EF6-D3CE-4F8F-A6E1-392A24113678Q37383695-1C95B2AD-067E-4078-B324-CD9074307194Q37618041-9AE533FF-429F-411A-87CF-301579FBE9DDQ37619111-BEA5D53F-D10C-4DEF-B9C4-049D6B3FE17BQ37821230-BA9B05DE-5F47-4D68-B072-2C874F2C0325Q37840092-9CFF5DD0-3B50-4F9B-9808-C5494378707FQ37937737-405EE70F-1CC9-4300-A000-250C12BFF93CQ38160246-437DB700-DB5C-42C0-88D3-BBBE010DCCCDQ38885511-933FAA68-5FBD-42B0-9909-9F9B65D759E9Q40005854-E322EB90-718F-4853-B47B-548C059A8711Q40077184-7C98CE71-8D19-42FE-8F3B-1BDC85C1B913Q41908740-63D90177-289B-4A18-9E7A-0130F3F5762EQ48256868-20EDE842-1C80-4692-8B75-F2F5B474CD6BQ56568322-8B5A861B-8435-4FBD-A7E1-1A20FFB38E7C
P2860
Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Chemically modified short inte ...... and in vivo for RNAi of HER-2.
@en
type
label
Chemically modified short inte ...... and in vivo for RNAi of HER-2.
@en
prefLabel
Chemically modified short inte ...... and in vivo for RNAi of HER-2.
@en
P2093
P2860
P1476
Chemically modified short inte ...... and in vivo for RNAi of HER-2.
@en
P2093
Alexandre V Lebedev
Antonina Rait
Esther H Chang
Gerald Zon
Kathleen F Pirollo
Richard I Hogrefe
P2860
P304
P356
10.1080/15257770600793885
P577
2006-01-01T00:00:00Z